On Demand: Outsmarting the Heart: A Novel Device Therapy Targeting the Neurohormonal Pathways in Heart Failure Patients-Presentation Slides

Presentation Slides

Pdf Summary

The document summarizes a novel device therapy called Barostim, which is designed to help heart failure patients by targeting the neurohormonal pathways responsible for disease progression. The therapy focuses on improving functional status, exercise capacity, and quality of life by enhancing baroreceptor signaling. <br /><br />Heart failure affects 6.7 million adults in the U.S., causing significant mortality and healthcare costs. Traditional management includes guideline-directed medical therapy (GDMT), which involves pharmacological treatments to reduce morbidity and mortality through neurohormonal blockade. However, despite GDMT, many patients remain at risk of complications and require additional interventions. <br /><br />Barostim offers a device-based therapy that provides Baroreflex Activation Therapy for patients with symptomatic heart failure even after GDMT optimization. The therapy is particularly targeted at patients not responding to Cardiac Resynchronization Therapy (CRT) and those facing recurrent hospitalizations. The document highlights the significant improvements observed in clinical trials related to exercise capability, New York Heart Association (NYHA) functional class, and quality of life for patients using Barostim. <br /><br />The therapy is especially suited for patients with LVEF 35% or less and NT-proBNP levels above 1600 pg/ml. Clinical results from PRISMA Health suggest a 57% reduction in heart failure-related hospitalizations post-Barostim implantation. <br /><br />The document also discusses procedural details for the successful implementation of the therapy in clinical settings, emphasizing the importance of team organization, evaluation standardization, routine reviews, and staying on top of billing and coding. Financial aspects are presented, such as Medicare reimbursement details for Barostim procedures, supporting its integration into multidisciplinary heart failure programs. Lastly, the document briefly mentions a service for prior authorization to streamline the process for implementing Barostim therapy.<br /><br />In summary, Barostim emerges as a promising adjunctive therapy for heart failure patients who continue to exhibit symptoms despite optimized GDMT, potentially reducing hospitalization rates and improving patient outcomes.

Keywords

Barostim

heart failure

neurohormonal pathways

Baroreflex Activation Therapy

quality of life

exercise capacity

NYHA functional class

clinical trials

hospitalizations

Medicare reimbursement